

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Grand Pharmaceutical Group Limited**  
**遠大醫藥集團有限公司\***  
*(Incorporated in Bermuda with limited liability)*  
**(Stock Code: 00512)**

### **VOLUNTARY ANNOUNCEMENT**

### **THE GROUP ESTABLISHES A STRATEGIC PARTNERSHIP WITH THE UNIVERSITY OF HONG KONG**

This announcement is made by the board of directors (the “**Board**”) of Grand Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Board is pleased to announce that the Group has established a strategic partnership with the University of Hong Kong (“**HKU**”) and its wholly-owned subsidiary, University of Hong Kong Versitech Limited (“**HKU Versitech**”) recently. The two parties will conduct in-depth cooperation in academic research, resource sharing, talent training and product development, and work together to promote the research and development of innovative drugs in the field of anti-infection and the industrialization of the research results. This collaboration will begin with the development of innovative antibacterial drugs. The relevant projects will be undertaken by Prof. Li Xuechen’s team, aiming at developing novel therapeutic solutions with improved efficacy and safety profiles to address unmet clinical needs in antibacterial therapy. Subsequently, HKU will grant the Group an exclusive license to its relevant intellectual property rights, with the Group fully responsible for the subsequent development, registration and commercialization, so as to efficiently realize the industrial transformation of cutting-edge scientific research results.

This collaboration marks another crucial step forward for the Group in linking with top international universities and deeply integrating cutting-edge academic research with industrial application.

Established in 1911, HKU is the territory’s oldest institute of higher learning and also an internationally recognized, research-led comprehensive university, which ranks 11th place in the 2026 QS World University Rankings, announced by global higher education analytics organization Quacquarelli Symonds (QS). HKU is committed to cutting-edge scientific research, and its research teams have achieved internationally leading accomplishments in protein chemical synthesis, peptide drugs, and innovative drug development. HKU Versitech is the commercial arm of HKU, and is responsible for managing the fostering of industry-academia collaboration and University’s research technology transfer.

Prof. Li Xuechen is Morningside Endowed Professor in Chemical Biology and Chair Professor in Medicinal Chemistry/Chemical Biology in the Department of Chemistry at the HKU. The research of Prof Li Xuechen lies in the interface of synthetic chemistry, medicinal chemistry and biology, spanning from innovative synthetic method development to biological studies and drug discovery, with the ultimate aim to develop novel therapeutics. At HKU, he has pioneered in the development of several innovative methods to synthesize and modify biomolecules including peptides, proteins and glycans. These methods open up new avenues for studying the biology and medicinal chemistry of biomolecules and provide new possibilities to generate biologics with new functional activities.

This collaboration is a significant step for both parties to explore a collaborative innovation model between industry, academia, and research. It can fully combine HKU's profound basic research experience in medicinal chemistry with the Group's mature clinical development and industrialization advantages, accelerate the overcoming of unmet clinical needs, and is expected to boost launching a number of high-quality innovative drugs and benefit patients worldwide.

The Group adheres to a strategy of synergistic innovative development among multiple business segments, and continuously advances the development of innovative products. In 2026, a number of innovative blockbuster products are expected to be launched and commercialized, with multiple business segments stepping up their efforts simultaneously to continuously enrich and improve the product portfolio, further solidifying the Group's global innovation layout. Among them, innovative products such as the world's first innovative dry eye treatment product, Varenicline Tartrate Nasal Spray, compound nasal spray Ryaltris<sup>®</sup> for the treatment of allergic rhinitis, adrenaline nasal spray Neffy<sup>®</sup> for treating type I allergic reactions, and lotilaner ophthalmic solution for the treatment of Demodex blepharitis, will be launched to the market one after another. The aforementioned products will further solidify the Group's pipeline layout in its advantageous areas, make breakthroughs in filling clinical gaps, address unmet treatment needs, help the Group open up new golden tracks, seize vast blue ocean incremental markets, and inject strong and lasting core growth momentum into long-term high-quality development.

In terms of R&D innovation and internationalization, the Group is expected to achieve several landmark milestones in 2026, continuously demonstrating its global innovation and R&D capabilities and its global clinical advancement strength. The Group's core blockbuster globally innovative drug for sepsis, STC3141, has made remarkable progress in its development. The product successfully met the pre-specified endpoint of the Phase II clinical trial in China in 2025. Currently, the Group is actively communicating with international authoritative regulatory agencies such as the FDA to optimize the clinical protocol and is fully advancing the preliminary preparations for the international multicenter clinical trial. In the future, it is expected to provide a breakthrough treatment option for nearly 50 million sepsis patients worldwide. The Group has completed the submission of a New Drug Application (NDA) for its radionuclide-drug conjugate (RDC) TLX591-CDx for the diagnosis of prostate cancer, and it is expected to be officially approved for commercialization in 2026. Furthermore, the Group's independently developed globally innovative FAP-targeted radionuclide conjugate drug GPN01530, for the diagnosis of solid tumors, is expected to conduct its Phase I/II clinical trial in the United States within the year; the globally innovative GPC-3-targeted product GPN02006, for the diagnosis of hepatocellular carcinoma (HCC), is expected to submit an Investigational New Drug (IND) application to the FDA within the year, demonstrating the steady implementation of the Group's global innovative R&D layout. With its continuously groundbreaking cutting-edge technologies, globally collaborative clinical system, and rich

pipeline of innovative radiopharmaceuticals, the Group's radiopharmaceutical segment has established globally leading R&D technology barriers and core competitive advantages, leading the wave of innovative development in the field of radiopharmaceutical diagnosis and treatment, and laying the most solid innovative foundation for the Group's long-term development.

The Group always puts focus on the R&D of innovative products and advanced technologies. Adhering to a patient-centered and innovation-driven approach, the Group will continue to increase its investment in world-class innovative products and advanced technologies to meet unmet clinical needs and enrich its product pipeline and improve supply chain. The Group adopts the strategy of "global expansion and dual-cycle operation", forming a new pattern of domestic and international cycles that synergize with each other. In this way, the Group can make full use of its industrial advantages and R&D capabilities, to accelerate the commercialization process for innovative products and provide patients with more advanced and diverse treatment options globally.

**Warning:**

**Whether the cooperation can contribute benefit have uncertainty. Shareholders and prospective investors of the Company are advised to exercise caution when dealing in the securities of the Company.**

*Note: In this announcement, the Chinese translations of organizations and products are unofficial translations and are for display purposes only.*

By order of the Board  
**Grand Pharmaceutical Group Limited**  
Chairman  
**Dr. Tang Weikun**

Hong Kong, 8 April 2026

*As at the date of this announcement, the Board comprises four executive directors, namely, Dr. Tang Weikun, Mr. Zhou Chao, Mr. Yang Guang and Ms. Lam Chit Yee Jessica, and four independent non-executive directors, namely, Ms. So Tosi Wan, Winnie, Dr. Xing Li Na, Dr. Pei Geng and Mr. Hu Yebi.*

*\* For identification purpose only*